Group 1 - The medical beauty sector increased by 0.18% on January 14, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 151.77, up 0.30%, and Jinbo Biological down 1.14% at 238.58 [1] Group 2 - The net inflow of main funds in the medical beauty sector was 5.91 million yuan, while retail funds saw a net inflow of 12.26 million yuan [1] - The main funds for Ai Meike had a net inflow of 17.77 million yuan, while retail funds had a net inflow of 4.15 million yuan [2] - Jinbo Biological experienced a significant net outflow of main funds at 43.53 million yuan, indicating a negative trend [2]

Core Viewpoint - The recent share reduction by the second largest shareholder, Guoshou Chengda, indicates potential challenges for Huaxi Biological, as the company faces declining performance and internal management issues [4][9]. Shareholder Activity - On January 13, Huaxi Biological's stock price increased by 2.25% to 47.34 yuan, with significant trading activity including 17 block trades at an average price of 42.89 yuan, reflecting a 9.4% discount [2][3]. - Guoshou Chengda, a subsidiary of China Life Insurance, has been executing a share reduction plan, having reduced its holdings from 6.01% to 5% after selling 485.25 million shares [4][5]. - The total cash generated from the recent share reductions amounts to approximately 2.1 billion yuan, with 1.28 billion yuan from regular trading and 825.89 million yuan from block trades [4][5]. Financial Performance - Huaxi Biological's revenue for 2023 decreased by 11.6% to 5.371 billion yuan, with net profit plummeting by 72.27% to 164 million yuan, resulting in a market value drop of about 80% from its peak [10]. - The company's skin science innovation business saw a 31.62% revenue decline in 2024, contributing to overall financial struggles [9][10]. - In the first three quarters of 2025, revenue fell by 18.36% to 3.163 billion yuan, while net profit decreased by 30.29% to 252 million yuan [11]. Market Position and Future Outlook - Huaxi Biological's peak stock price reached 308.44 yuan in July 2021, but has since experienced a significant decline, now trading below its initial public offering price of 47.79 yuan [6][7]. - The company is undergoing strategic adjustments in its product lines, with a focus on transforming its personal health consumer products into skin science innovations [9]. - Analysts have issued a "reduce" rating for Huaxi Biological, with a target price of no more than 34.7 yuan, predicting a net profit of 400 million yuan for 2025 [12].

Core Viewpoint - The recent share reduction by the state-owned shareholder of Huaxi Biological indicates ongoing challenges for the company, including internal personnel changes and declining performance in its core business segments [5][6]. Group 1: Shareholder Activity - On January 13, Huaxi Biological's stock price increased by 2.25% to 47.34 yuan, with significant trading activity including 17 block trades at an average price of 42.89 yuan, reflecting a 9.4% discount [1][2]. - The second-largest shareholder, Guoshou Chengda, has been executing a share reduction plan, having reduced its holdings from 6.01% to 5% after selling 485.25 million shares [3][4]. - Guoshou Chengda has been reducing its stake since November 2022, with plans to sell up to 963.35 million shares by February 2026, and has already cashed out approximately 2.1 billion yuan from previous sales [3][4]. Group 2: Financial Performance - Huaxi Biological's revenue has faced significant pressure, with a reported 11.6% decline to 5.371 billion yuan and a net profit drop of 72.27% to 164 million yuan [7]. - The company's skin science innovation business saw a 31.62% revenue decline to 2.569 billion yuan in 2024, attributed to intensified market competition [6][8]. - In the first three quarters of 2025, revenue fell by 18.36% to 3.163 billion yuan, with net profit decreasing by 30.29% to 252 million yuan, although the third quarter showed some improvement in net profit due to reduced sales expenses [8][9]. Group 3: Market Sentiment and Future Outlook - The ongoing share reductions by major shareholders and the company's declining performance suggest a critical juncture for Huaxi Biological, raising concerns about its future growth potential [5][6]. - Nomura Orient International Securities has issued a "reduce" rating for Huaxi Biological, setting a target price of no more than 34.7 yuan, predicting a net profit of 400 million yuan for 2025 [10].

Core Viewpoint - Huaxi Biological conducted a significant block trade on January 13, with a total transaction volume of 1.359 million shares and a transaction amount of 58.2872 million yuan, reflecting a discount of 9.40% compared to the closing price of the day [2][3]. Trading Activity - On January 13, there were 17 transactions on the block trading platform for Huaxi Biological, with an average transaction price of 42.89 yuan per share [2]. - In the last three months, Huaxi Biological has seen a total of 46 block trades, amounting to 141 million yuan [3]. - The closing price of Huaxi Biological on the day of the report was 47.34 yuan, which represents a 2.25% increase, with a daily turnover rate of 2.40% and a total transaction amount of 546 million yuan [3]. Institutional Participation - Institutional proprietary seats were involved in 9 of the transactions, with a total transaction amount of 22.1739 million yuan, indicating a net purchase of the same amount [2]. - The latest margin financing balance for Huaxi Biological is 555 million yuan, which has increased by 38.4969 million yuan over the past five days, reflecting a growth rate of 7.45% [4].

Core Viewpoint - On January 13, 14 stocks from the STAR Market experienced block trading, with a total transaction amount of 315 million yuan and a cumulative trading volume of 9.96 million shares [1]. Group 1: Trading Overview - A total of 38 block trades were recorded for the 14 STAR Market stocks, with the highest transaction amount attributed to Hu Silicon Industry, which had a trading volume of 6.61 million shares and a transaction amount of 149 million yuan [1]. - Other notable transactions included Huaxi Biological and Mingwei Electronics, with transaction amounts of 58.29 million yuan and 26.62 million yuan, respectively [1]. - The average price of block trades for the stocks showed significant variations, with some stocks trading at discounts to their closing prices, such as Zhongkong Technology at a discount rate of 27.20% [1][4]. Group 2: Price Performance - The STAR 50 Index fell by 2.80% on the same day, with 167 stocks, or 27.83%, experiencing price increases [1]. - Among the stocks involved in block trading, the average price change was a decrease of 0.10%, with notable gainers including Zhuoyi Information, Zhongkong Technology, and Huaxi Biological, which saw increases of 13.13%, 9.90%, and 2.25%, respectively [1]. - Conversely, stocks like Bolite, Mingwei Electronics, and Hu Silicon Industry faced declines of 11.41%, 4.87%, and 3.27% [1]. Group 3: Institutional Participation - Out of the block trades, 13 transactions involved institutional buyers or sellers, focusing on three stocks, with Huaxi Biological leading in institutional buy amounts at 22.17 million yuan [2]. - Other significant institutional purchases included Tiannai Technology and Yunlu Co., with buy amounts of 7.09 million yuan and 2.01 million yuan, respectively [2]. - In terms of capital flow, four stocks saw net inflows, with Huaxi Biological, Yunlu Co., and Lante Optical leading in net inflow amounts of 67.52 million yuan, 14.59 million yuan, and 10.73 million yuan, respectively [2].

Summary of China Cosmetics Sector Conference Call Industry Overview - The China cosmetics sector is expected to experience a reset for higher-quality growth in 2026, moving away from reliance on high-cost Key Opinion Leaders (KOLs) and focusing on popular core SKUs. This shift has led to a contraction in Net Profit Margin (NPM) due to deleveraging impacts, despite improvements in Return on Investment (ROI) [1][2]. Key Trends and Insights - **Consumer Acquisition Costs**: Monitoring new consumer acquisition costs will be critical, especially as channel migration benefits diminish and the ingredient cycle remains ambiguous. Anti-involution policies will also play a significant role [1]. - **Branding Strategy**: Branding is anticipated to be the most effective strategy for consumer engagement and new product launches in 2026. Companies with high repurchase rates and cost-efficient omni-channel strategies are better positioned for success [1][2]. - **Market Dynamics**: The cosmetics market is expected to grow at a normalized rate, with growth projected at less than 1x GDP growth. The market is forecasted to see a 2.1% increase in beauty spending in 2026, with a mix of onshore and offshore market performance [17][18]. Company-Specific Insights - **Mao Geping Cosmetics (MGP)**: Upgraded from Neutral to Buy with a target price increase from HK$89 to HK$105, reflecting a 27% upside. The company is noted for strong branding and a balanced channel presence, with a forecasted sales and net income CAGR of 23% and 22% from 2025 to 2027, respectively [2][9]. - **Giant Biogene**: Maintained as Buy, with a target price lowered from HK$71 to HK$46, indicating a 36% upside. The company is expected to recover with new skincare products and a focus on medical aesthetics, projecting sequential growth of -8%/+12%/+17% YoY for 1H26E/2H26E/2027E [2][9]. - **Shanghai Jahwa**: Target price reduced from RMB 31 to RMB 28, with a 22% upside. The company is on a turnaround trajectory with improving margins and cash flow [2][9]. - **Proya Cosmetics**: Remains Neutral as the company is expected to moderate organic growth while awaiting more execution on white space exploration [2][9]. - **Botanee Biotech**: Neutral rating with early signs of a potential turnaround but lacking clear growth drivers [2][9]. - **Bloomage Biotech**: Maintained as Sell due to downside risks in skincare and muted growth in medical aesthetics amid a mature product cycle [2][9]. Market Performance and Projections - **E-commerce Trends**: Tmall is expected to maintain strong growth momentum, supported by anti-involution measures. Douyin's performance has been softer than expected, with a significant decline in KOL channel performance [19][21]. - **Sales Growth Expectations**: The cosmetics sector is projected to see sustained GMV growth on Tmall, while Douyin is expected to experience a narrowing gap in growth rates compared to Tmall [20][21]. Conclusion - The China cosmetics sector is poised for a shift towards higher-quality growth in 2026, with branding and strategic channel management becoming increasingly important. Companies that adapt to these changes and focus on core products are likely to outperform in the evolving market landscape [1][2][19].

| 交易日期 | 证券简称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 类出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-13 | 华熙生物 | 688363 | 42.89 | 325.96 | 7.6 | | 10 | 조 | | 2026-01-13 | 华熙生物 | 688363 | 42.89 | 300.23 | 7 | 机构专用 | | 图 | | 2026-01-13 | 华配生物 | 688363 | 42.89 | 240.18 | 5.6 | 机构专用 | | 190 | | 2026-01-13 | 华熙生物 | 688363 | 42.89 | 214.45 | 5 | | | M | | 2026-01-13 | 华熙生物 | 688363 | 42.89 | 214.45 | ટ | | | KO | | 2026-01-13 | 华赋生物 | 688363 | 42.89 | 214.45 | 5 | | | 香 | ...

Core Viewpoint - Huaxi Biological has shown a stock price increase of 8.15% year-to-date, with a recent trading volume indicating active market participation and a total market capitalization of 22.754 billion yuan [1][2]. Financial Performance - For the period from January to September 2025, Huaxi Biological reported a revenue of 3.163 billion yuan, representing a year-on-year decrease of 18.36%. The net profit attributable to shareholders was 252 million yuan, down 30.29% compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 1.138 billion yuan, with 528 million yuan distributed over the past three years [3]. Stock Market Activity - As of January 13, the stock price of Huaxi Biological was 47.24 yuan per share, with a trading volume of 198 million yuan and a turnover rate of 0.88% [1]. - The stock has experienced a 5.19% increase over the last five trading days and a 4.51% increase over the last 20 days, while it has decreased by 11.25% over the last 60 days [2]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Huaxi Biological was 30,100, a decrease of 0.62% from the previous period. The average number of circulating shares per shareholder increased by 0.62% to 16,014 shares [2][3]. - Major institutional shareholders have reduced their holdings, with significant decreases noted in the top ten circulating shareholders [3].

Investment Rating - The report assigns an "Accumulate" rating for the industry [5] Core Insights - With the proliferation of AI tools, GEO (Generated Engine Optimization) is expected to become a new marketing paradigm, allowing e-commerce operation companies to leverage their understanding of platforms and content marketing to capture incremental brand marketing demand [2][5] - The Chinese GEO market is rapidly growing, with a year-on-year increase of 215% in Q2 2025, and over 78% of enterprise decision-makers prioritizing AI search optimization in their digital transformation strategies [5] - The transition from traditional SEO to GEO is anticipated to reshape brand marketing strategies, with e-commerce operation companies positioned to benefit from this shift due to their close collaboration with platforms and deep understanding of consumer insights [5] Summary by Sections Industry Overview - The report highlights the shift from SEO to GEO as a significant change in digital marketing strategies, emphasizing the need for brands to adapt to new consumer information acquisition methods [2][5] Investment Recommendations - E-commerce operation companies such as Ruoyuchen, Yiwang Yichuang, and Shuiyang Co. are recommended as key players to watch, with additional related companies including Qingsong Technology, Liren Lizhuang, Baozun E-commerce, and Kaichun Co. [5] Market Trends - The report notes that traditional search engine traffic is projected to decline by 25% by 2026, while AI chatbots and other virtual AI optimization methods are expected to capture more market share [5] - The conversion rate for businesses using GEO is reported to be 2.8 times higher than that of traditional search engines, with a 40% reduction in user decision-making cycles [5]

Core Insights - The beauty industry is undergoing a significant transformation as consumers prioritize product ingredients and efficacy over marketing narratives and brand stories [1][2] - The competition among companies is shifting from traditional marketing to a focus on scientific validation and technical authority, particularly regarding core ingredients [1][3] Group 1: Industry Dynamics - The battle for defining the "ingredient king" is exemplified by the prolonged conflict between Huaxi Biological and Juzhi Biological over recombinant collagen, highlighting the industry's shift towards scientific discourse [1][2] - Companies are increasingly engaged in disputes over intellectual property and scientific narratives, as seen in the conflict between medical company Aierfu and skincare brand Zhanmeiya, which revolves around the storytelling of scientific advancements [3] Group 2: Market Competition - The competition for established, cash-generating scientific products is illustrated by the dispute between Shuiyang Co. and Ruoyu Chen over the agency rights for the Spanish brand "Mestique," which has shown remarkable growth in the Chinese market [5][6] - The financial performance of companies varies significantly, with some experiencing revenue growth alongside increased R&D spending, while others face declining revenues despite high R&D investments [6][7] Group 3: Consumer Behavior - A significant shift in consumer preferences is noted, with 58.8% of consumers prioritizing product ingredients in their purchasing decisions, indicating a growing demand for transparency and efficacy [15][21] - The rise of the "ingredient party" has led to increased scrutiny of product claims, pushing companies to provide credible testing reports and validate their ingredients [15][21] Group 4: Future Trends - The beauty industry's future is marked by a "scientific arms race," with brands striving to establish their authority in scientific research and ingredient validation [8][16] - Companies are exploring unique natural ingredients and integrating skincare with makeup, reflecting a trend towards holistic beauty solutions [20][21]